Orsoten capsules 120mg, No. 42
Expiration Date: 05/2027
Russian Pharmacy name:
Орсотен капсулы 120мг, №42
Long-term treatment of patients with conditions such as:
obesity (body mass index (BMI)? 30 kg / m2);
overweight (BMI? 28 kg / m2), incl. having risk factors associated with obesity, in combination with a moderately low-calorie diet.
Orsotene can be administered in combination with hypoglycemic drugs and / or a moderately low calorie diet in overweight or obese type 2 diabetes patients.
Inside, washed down with water, immediately before each main meal, during meals or no later than an hour after meals.
The recommended single dose of orlistat is 1 caps. 120 mg each. If the meal is skipped or the meal does not contain fat, then orlistat can be skipped.
Doses of orlistat over 120 mg 3 times a day do not enhance its therapeutic effect. The duration of therapy is no more than 2 years. No dose adjustment is required for elderly patients or patients with impaired liver or kidney function.
The safety and efficacy of using orlistat in the treatment of children under the age of 18 has not been established.
| Capsules | 1 caps. |
| active substance: | |
| orsoten semi-finished product-granules | 225.6 mg |
| (based on the active substance orlistat - 120 mg) | |
| the composition of the semi-finished product-granules (100 g): orlistat - 53.1915 g; MCC | |
| excipients: MCC | |
| hypromellose capsules | |
| capsule shell composition | |
| capsule body: hypromellose; water; titanium dioxide (E171) | |
| capsule cap: hypromellose; water; titanium dioxide (E171) |
hypersensitivity to orlistat or any other components of the drug;
chronic malabsorption syndrome;
cholestasis;
pregnancy;
lactation;
children under 18 years of age (efficacy and safety have not been studied).
pharmachologic effect
Lipase inhibitor. When taken orally, orlistat inhibits gastric and pancreatic lipases. As a result, the breakdown of dietary fats is disrupted and their absorption from the gastrointestinal tract decreases. With systematic use, this effect leads to a decrease in body weight in obese patients. Orlistat is practically not absorbed from the gastrointestinal tract and, therefore, practically does not have a resorptive effect.
Side effect
Possibly: oily discharge from the rectum, flatulence, 'fat' stools, frequent bowel movements, urge to defecate, fecal incontinence.
Application during pregnancy and lactation
Orlistat is used with extreme caution during pregnancy and lactation.
special instructions
It must be borne in mind that the frequency and severity of side effects increase with an increase in the content of fat in food. As the fat content of food decreases, the likelihood of side effects decreases. It is recommended that the amount of fat consumed per day is distributed fairly evenly across all meals. In the course of treatment, as the body weight decreases, it is possible to improve the course of pathological processes that are often associated with obesity, incl. arterial hypertension, diabetes mellitus, lipid metabolism disorders.
Drug interactions
It has been shown that orlistat leads to a decrease in the absorption of beta-carotene, ?-tocopherol from the gastrointestinal tract.